The aim of this project, which has been commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Single Technology Appraisal process, is to review the submission of the pharmaceutical company on the evidence for the clinical and cost-effectiveness of Teduglutide for treating short bowel syndrome in adults and children. The overall clinical evidence submitted by the company (Shire Pharmaceuticals) responsible for manufacturing Teduglutide (Revestive®), consists of three RCTs for the adult population plus three non-randomised extension studies and one non-randomised study for the paediatric population. For the adult population the company focus specifically on the results of the STEPS trial. The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for the project and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company.

Based on the findings of the company submission and of the ERG’s critique, NICE will release appropriate clinical guidance. 


Miriam Brazzelli;